{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:15:19Z","timestamp":1781918119539,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Bio & Medical Technology Development Program of the National Research Foundation (NRF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT & Future Planning","doi-asserted-by":"publisher","award":["2017M3A9E8029714"],"award-info":[{"award-number":["2017M3A9E8029714"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["2017-32-0033"],"award-info":[{"award-number":["2017-32-0033"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejso.2018.10.053","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T13:48:21Z","timestamp":1539265701000},"page":"644-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"45","author":[{"given":"Yong Jae","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Shin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2018.10.053_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3802\/jgo.2008.19.3.169","article-title":"Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC\/IV ovarian cancer","volume":"19","author":"Yoo","year":"2008","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ygyno.2009.06.038","article-title":"Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer","volume":"115","author":"Zivanovic","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000131270","article-title":"Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer","volume":"31","author":"Kim","year":"2008","journal-title":"Onkologie"},{"key":"10.1016\/j.ejso.2018.10.053_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2006.02.024","article-title":"Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer","volume":"103","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3349\/ymj.2016.57.3.580","article-title":"Clinical significance of CA125 level after the first cycle of chemotherapy on survival of patients with advanced ovarian cancer","volume":"57","author":"Lee","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ejso.2018.10.053_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jamaoncol.2016.1842","article-title":"Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer","volume":"2","author":"Esselen","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2004.09.020","article-title":"CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma","volume":"96","author":"Tate","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2012.02.006","article-title":"Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy","volume":"125","author":"Rodriguez","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2013.08.005","article-title":"Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience","volume":"131","author":"Fagotti","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejso.2018.10.053_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2017.11.023","article-title":"Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer","volume":"148","author":"Lee","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","volume":"106","author":"Wimberger","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib15","first-page":"140","article-title":"Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma","volume":"41","author":"Geisler","year":"1996","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.ejso.2018.10.053_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2008.01.035","article-title":"Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel\/platinum chemotherapy: a French multicentric study","volume":"109","author":"Riedinger","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdi012","article-title":"Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?","volume":"16","author":"Crawford","year":"2005","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2018.10.053_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000271445","article-title":"Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?","volume":"30","author":"Sevelda","year":"1990","journal-title":"Gynakol Rundsch"},{"key":"10.1016\/j.ejso.2018.10.053_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2014.09.005","article-title":"CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy","volume":"135","author":"Pelissier","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2018.10.053_bib20","first-page":"3410","article-title":"The effect of CA125 nadir level on survival of advanced-stage epithelial ovarian carcinoma after interval debulking surgery","volume":"8","author":"Zeng","year":"2017","journal-title":"J\u00a0Canc"},{"key":"10.1016\/j.ejso.2018.10.053_bib21","first-page":"1002","article-title":"Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis","volume":"79","author":"Makar","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejso.2018.10.053_bib22","first-page":"13","article-title":"Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature","volume":"2","author":"Gupta","year":"2009","journal-title":"J\u00a0Ovarian Res"},{"key":"10.1016\/j.ejso.2018.10.053_bib23","first-page":"1","article-title":"CA-125: an inaccurate surveillance tool immediately after cytoreductive surgery and hyperthermic intraoperative chemotherapy (CRS-HIPEC)?","author":"Shannon","year":"2017","journal-title":"Int J Hyperther"},{"key":"10.1016\/j.ejso.2018.10.053_bib24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/bjc.1988.250","article-title":"Peritoneal trauma releases CA125?","volume":"58","author":"Redman","year":"1988","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejso.2018.10.053_bib25","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1097-0142(19871115)60:10<2437::AID-CNCR2820601015>3.0.CO;2-K","article-title":"Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors","volume":"60","author":"Fleuren","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2018.10.053_bib26","first-page":"407","article-title":"Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer","volume":"168","author":"Talbot","year":"1989","journal-title":"Surg Gynecol Obstet"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318314537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318314537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:28:28Z","timestamp":1760059708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798318314537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0748798318314537"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2018.10.053","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2018.10.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}